UNSPSC 51431709: Diltiazem malate

This classification denotes a calcium channel blocker with the molecular formula C22H26N2O4S.C4H6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14Y6444DRP, chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-5-(2-(di-methylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-(2s-cis)-, (s)-hydoxybutanedioate (1:1) but more generally known as diltiazem malate, which bears US NIH Compound Identifier 3037122.

UNSPSC 51431709 Diltiazem malate is a Commodity code representing a specific pharmaceutical active ingredient and formulation used in emergency medical services and pharmacy benefit programs across state and local jurisdictions. State and local governments procure diltiazem products primarily as part of broader advanced life support medication inventories for emergency response agencies and through cooperative purchasing arrangements that aggregate demand across multiple jurisdictions and agencies. The work involves supplying pharmaceutical products that meet FDA compliance requirements, maintain specified shelf life and expiration standards, and comply with Drug Supply Chain Security Act (DSCSA) certification and cGMP manufacturing standards. Issuing bodies include city purchasing departments acquiring on behalf of fire rescue and emergency medical services, state health and human services agencies managing pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating procurement across participating state and local facilities.

Recent activity shows diltiazem solicitations across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 (due April 8, 2026) for 1,020 units of diltiazem 25mg vials as part of a $40,000 advanced life support medications contract for Tampa Fire Rescue, with a Small Local Business Enterprise sheltered market designation and a 5 percent bid discount for SLBE participation. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with products required in the marketplace by May 15, 2026 and resulting agreements effective July 1, 2026.